BEYOND SYMPTOM CONTROL Developing therapies to help people with orphan conditions of the brain and nervous system live their lives to the fullest. Who We Are Noema Pharma is a biotech company developing groundbreaking therapies to address the most debilitating symptoms in orphan conditions of th ...
Location: Switzerland, Basel-City, Basel
Employees: 11-50
Total raised: $320.97M
Founded date: 2020
Investors 4
| Date | Name | Website |
| 07.04.2021 | Sofinnova ... | sofinnovap... |
| 09.05.2023 | Jeito Capi... | jeito.life |
| - | Gilde Heal... | gildehealt... |
| 16.03.2023 | Forbion | forbion.co... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 14.12.2024 | Series B | $147.41M | - |
| 07.03.2023 | Series B | $112M | - |
| 20.12.2020 | Series A | $61.56M | - |
Mentions in press and media 28
| Date | Title | Description |
| 17.01.2025 | New executives to facilitate further growth | Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, is advancing a portfolio of transformative, first-in-disease therapeutics targeting neuroscience-based conditions with high unmet... |
| 18.12.2024 | Noema Pharma Appoints Volker Knappertz, M.D., as Executive VicePresident of Research &Development | BASEL, Switzerland, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Noema Pharma, aclinical-stage biotech company targeting debilitating central nervoussystem (CNS) disorders, today announced the appointment of VolkerKnappertz, M.D., as Executive Vice Pr... |
| 14.12.2024 | Noema Pharma: Biotech Company Closes Series B At About $147 Million | Noema Pharma – a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders – announced the closing of a Series B extension financing round with an investment from EQT Life Sciences, bringing the total capi... |
| 11.12.2024 | Noema Pharma extends Series B financing round, closing at CHF 130 Million ($147 Million) | - EQT Life Sciences expands the Series B with additional capital, alongside continued support from existing investors, including, Forbion, Jeito Capital, Sofinnova Partners, Gilde Healthcare, Polaris Partners, Invus, and UPMC Enterprises BA... |
| 11.12.2024 | Noema Pharma extends Series B funding to CHF 130 million | EQT Life Sciences’ LSP 7 fund has invested in Noema Pharma. The clinical-stage biotech company headquartered in Basel is developing a pipeline of first-in-disease therapeutics that address central nervous system (CNS) disorders. The Series... |
| 11.12.2024 | EQT Life Sciences Leads Series B Extension in Noema Pharma, Raising Total Series B Financing to CHF 130 million | EQT Life Sciences Leads Series B Extension in Noema Pharma, Raising Total Series B Financing to CHF 130 million Wed, Dec 11, 2024 09:30 CET Report this content Proceeds will be used to enable key late-stage clinical trial readouts for asset... |
| 21.10.2024 | A new step in the clinical development | Based-based company NUCLIDIUM announced the imaging of the first patient in a Phase 1 clinical trial for its radiotracer, 61Cu-NuriPro™, aimed at diagnosing and staging prostate cancer. The phase 1 clinical trial aims at evaluating the com... |
| 15.08.2024 | Clinical advancements at ImmunOs Therapeutics and Noema Pharma | ImmunOs Therapeutics AG, a biopharmaceutical company using its HLA-based technology platform to develop first-in-class and innovative therapeutics for the treatment of cancer and autoimmune diseases, has expanded its ongoing Phase I clinic... |
| 27.05.2024 | Biotechs record clinical trial successes | Noema Pharma, a clinical-stage biotech targeting debilitating neuroscience disorders, has treated the first patient in an open-label Phase 2a study (NOE-PPM-201) evaluating the safety and efficacy of NOE-115, a broad-spectrum monoamine mod... |
| 22.05.2024 | Noema Pharma Announces First Patient Dosed in Phase 2a Study of NOE-115, a First-In-Class Investigational Therapy for the Treatment of Vasomotor Symptoms and Additional Symptoms Associated with Menopa... | NOE-115 has the potential to benefit Vasomotor Symptoms (VMS) during menopause as well as associated clinical challenges including weight gain, daytime fatigue, and cognitive symptoms BASEL, Switzerland, May 22, 2024 – Noema Pharma AG, a cl... |
Show more